deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT02542696

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Sponsor: Sumitomo Pharma America, Inc.

Conditions Parkinson Disease
Interventions APL-130277
Updated 21 times since 2017 Last updated: Oct 31, 2023 Started: Aug 31, 2015 Primary completion: Nov 8, 2022 Completion: Nov 8, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Parkinson Disease, this trial is completed. The trial is conducted by Sumitomo Pharma America, Inc. and has accumulated 21 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Dec 2020 · 12 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Sep 2023 · 9 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Sep 2023 — Dec 2023 [monthly]

    Completed PHASE3

▶ Show 16 earlier versions

  1. Dec 2022 — Sep 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jul 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  3. May 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Jan 2022 — May 2022 [monthly]

    Recruiting PHASE3

  5. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Dec 2019 — Dec 2020 [monthly]

    Recruiting PHASE3

  9. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  10. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  11. Apr 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  12. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE3

  13. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  14. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  15. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sumitomo Pharma America, Inc.
Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Atlanta, United States , Augusta, United States , Aurora, United States , Baltimore, United States , Barcelona, Spain , Birmingham, United States , Boca Raton, United States , Bochum, Germany , Brooklyn, United States and 56 more locations